Krüppel-like factor 4 is a zinc finger protein with dual functions that can act as a transcriptional activator and repressor of genes involved in cell proliferation, differentiation, and apoptosis. Although most studies have focused on terminally differentiated epithelial cells, evidence suggests that Krüppel-like factor 4 regulates the development and function of the myeloid and lymphoid blood lineages. The ability of Krüppel-like factor 4 to dedifferentiate from somatic cells into pluripotent stem cells in cooperation with other reprogramming factors suggests its potential function in the preservation of tissue-specific stem cells. Additionally, emerging interest in the redifferentiation of induced pluripotent stem cells into blood cells to correct hematologic deficiencies and malignancies warrants further studies on the role of Krüppel-like factor 4 in steady-state blood formation.
Introduction
The complex process of blood formation is regulated by an orderly pattern of gene expression that maintains HSCs in a resting state, while preserving their capacity to differentiate on demand into different blood lineages. This gene-expression program drives the differentiation of small and undifferentiated HSCs, via hematopoietic progenitor cells at different stages of lineage determination and differentiation, into mature blood cells with varying subcellular complexity. These morphologic changes include multiple nuclei (megakaryocytes), no nuclei (RBCs), polylobulated nuclei (neutrophils), and the presence of cytosolic granules (eosinophils, basophils, and NK cells). The identification of the role of transcription factors during ontogeny has been achieved by the development of mouse models with the embryonic or the somatic deletion of corresponding genes. These transcription factors coordinate a pattern of gene expression that unfolds during the process of blood formation, whereas the expression of genes required for stem cell "stemness" is suppressed upon differentiation. In this review, we summarize the current knowledge of KLF4 gene expression and function in nonhematopoietic and hematopoietic cells and then focus on the roles of KLF4 in hematopoiesis under physiologic conditions.
KLFs are a family of transcription factors involved in disparate cellular processes with structural and functional homology to the transcription factor Sp1. Given the widespread expression of KLFs in different tissues and their regulatory role in cell proliferation and differentiation, these factors have important roles in the regulation of normal and malignant tissue homeostasis [1] [2] [3] . Phylogenetic analysis and functional clustering have been used to classify KLF4 into a subgroup, along with KLF1, KLF2, KLF5, KLF6, and KLF7 [1] . KLF4 was initially termed gut KLF because of its discovery in the intestinal epithelium, although KLF4 is also expressed in epithelial cells from other tissues, such as the skin and lung [4, 5] . In addition to postmitotic and terminally differentiated epithelial cells, KLF4 is expressed in other tissues, such as the thymus, testis, cornea, neonatal myocytes, and NK and T cells [6] [7] [8] [9] [10] . In cancer, KLF4 has dual functions as a tumor suppressor (i.e., colon and stomach cancer) and as an oncogene (i.e., breast cancer), which has been reviewed extensively elsewhere [3, [11] [12] [13] . These properties in the carcinogenesis process stem from the regulation of cell cycle (e.g., p21 and p53), oncogenic signals (e.g., Ras, Wnt, hormone receptors, TGF-b, Notch1), cell survival, oncogenic transformation, and metastasis [3] . In the hematopoietic system, KLF4 "suppresses" leukemogenesis in B cell non-Hodgkin and Hodgkin lymphomas, multiple myeloma, and AML [14] [15] [16] [17] , whereas the "protooncogenic" functions of KLF4 in leukemia have not yet been described. Before discussing the role of KLF4 in hematopoietic cells, we summarize the current knowledge of how KLF4 regulates gene expression gained from studies carried out in epithelial and cancer cells. These mechanisms range from epigenetic and transcriptional control (KLF4-DNA or KLF4-protein interactions) to tethering genomic structures.
REGULATION OF GENE EXPRESSION

Transcriptional regulation by DNA binding and protein-protein interactions
The KLF4 protein has 3 distinct functional domains that are involved in DNA binding, gene activation, and gene repression. A total of 3 zinc fingers mediates the binding of KLF4 to GC-rich sequences (i.e., CACCC) found in gene regulatory promoters and enhancers, which results in the recruitment of coactivators or corepressors in a cell context-dependent manner (Fig. 1) . For example, recruitment of the coactivator p300/CBP to KLF4 bound to DNA opens chromatin and increases gene transcription by acetylating both KLF4 and histone tails. Conversely, recruitment of the corepressor HDAC3 by KLF4 synergizes to repress the expression of target genes [18] [19] [20] . Interestingly, the ability of KLF4 to bind methylated and nonmethylated CpG dinucleotides with a similar affinity suggests a potential role in the regulation of hypermethylated genes. This property of recognizing methylated and nonmethylated cytosines can be decoupled by protein mutagenesis of the zinc finger domains [21, 22] . Therefore, KLF4 likely modulates the expression of methylated proto-oncogenes or tumor suppressor genes during carcinogenesis, as indicated by the increased genomic methylation that accompanies carcinogenesis.
In addition to recruiting coactivators/repressors, KLF4 regulates gene expression by protein-to-protein interactions with proteins that are bound to gene regulatory regions (Fig. 1) . For example, b-catenin directly activates the gene Tert in association with KLF4 but independently of its canonical partners TCF3 and TCF4 [23] . Although it has been demonstrated that the loss of KLF4 prevents the recruitment of b-catenin to the Tert locus, the protein domains that mediate b-catenin-to-KLF4 interactions and whether KLF4 binding to DNA is required to activate the Tert gene have not yet been determined. These findings should help to define more clearly how KLF4 contributes to the maintenance of telomerase activity, which could have implications in both normal stem cells and human cancers in which telomere regulation has been frequently associated.
Regulation of the epigenome
Chemical changes to DNA (methylation of CpG sites) and histone proteins (acetylation and methylation of histone tails), i.e., the epigenome, can result in changes in chromatin structure and gene activation. Although epigenetic regulation has recently become a widely studied topic, it is not clear whether KLF4 directly regulates the expression of genes involved in shaping the epigenome in normal and cancerous cells, although some findings do support this paradigm. For example, 1 study found that KLF4 expression reduces the levels of DNA methylation in the proximal promoter of the gene nephrin and other epithelial markers of podocytes, while increasing DNA methylation in mesenchymal genes [24] . Additionally, KLF4 could prevent the binding of Dnmt1 to hypomethylated promoters and increase the association of acetyl-H3K9 to this region [24] . However, that study did not evaluate genome-wide changes and focused on the methylation of a few CpGs located in the promoters of the nephrin and vimentin genes. Regarding acetylation patterns, KLF4 cooperates with histone acetyltransferases (i.e., p300) and histone demethylases (KDM5a, KDM6a, and KDM6b) in the activation of the POU5F1 gene in mouse neural stem cells [25] . More studies will be needed to evaluate the role of KLF4 in the maintenance of the DNA methylome and epigenetic marks in normal and malignant cells.
Formation of higher chromatin structures
Transcription factors often participate in the formation of nuclear structures that extend beyond the proximal promoter to regulate gene expression via long-range interactions. Several studies have shown that KLF4 participates in higher-order chromatin structures, particularly in ESCs and reprogrammed iPSCs (Fig. 1) . The binding of KLF4 to the proximal Lefty1 promoter mediates interactions with Oct3/4 and Sox2 bound to a distal enhancer that is located upstream of this promoter in ESCs [26] . A combination of fluorescence in situ hybridization and circular chromosome capture with high-throughput sequencing (4C-seq) later revealed that KLF4 facilitates long-range interactions in the Oct4 gene by recruiting cohesin independently of KLF4 binding to the Oct4 locus [27, 28] . Based on these findings, a model of higher chromatin structure that regulates the reprogramming of PSCs was postulated, in which KLF4 displays dual functions by binding to the proximal promoter of the Oct4 gene, along with Oct4 and Sox2, and then facilitating interactions of the Oct4 locus with distal chromosomal enhancers via the recruitment of cohesin [27] . It may be interesting to elucidate whether KLF4 acts similarly at other pluripotent loci and perhaps more generally in hematopoietic cells.
KLF4-regulated genes
Several genes regulated by KLF4 have been described (predominantly in epithelial cells) to have disparate functions that range from the regulation of cell proliferation, survival, and differentiation to energy metabolism ( Table 1 and the references therein). In most terminally differentiated and resting cells, KLF4 induces cell-cycle arrest by activating inhibitors of CDKs, such as p21, and repressing the expression of cyclins (i.e., D1, B1), which play a critical role in the G1-to S-phase transition. However, the regulation of KLF4 and p21 in cancer can have tumor-suppressor or oncogenic activities in a tissue-dependent manner [3, 76] . Likewise, KLF4 can activate or repress p53, depending on the cell type. Thus, loss or inactivation of KLF4 could lead to the promotion or inhibition of tumor growth [76] . In terms of cell survival, KLF4 can induce cell death, in part, by repressing antiapoptotic molecules (Bcl2), while also activating proapoptotic proteins (Noxa, Puma).
Self-renewal is a specialized type of cell division that generates daughter cells with the same properties as the parental cell. This characteristic feature of stem cells is critical to balance differentiating versus self-renewing cell divisions to support the need to regenerate damaged tissues without exhausting the stem cell pool. KLF4 promotes self-renewal in ESCs by activating the pluripotent genes Nanog, Oct4, and Sox2 via a transcriptional triad that also includes KLF2 and KLF5, as we describe later. Interestingly, the ability to bind specific target genes, as revealed by protein crystallography, appears to be imprinted in the protein structure itself, as the 2 C-terminal zinc fingers are required for macrophage differentiation, whereas the first zinc finger is more critical for self-renewal [77] . Cells generate energy in the form of ATP by oxidizing glucose into pyruvate in a process known as glycolysis. LDHA, a metabolic enzyme that converts pyruvate into lactate and oxidizes the reduced form of NADH to NAD + in the final step of anaerobic glycolysis, is up-regulated in many tumors and associated with disease stage and metastasis. One report has shown that the expression of KLF4 and LDHA is negatively correlated in pancreatic cancer as a consequence of direct binding and repression by KLF4 in the promoter region of the LDHA gene. The PFK enzyme plays an essential role in the regulation of glycolysis by converting fructose 6-phosphate into fructose 1,6-biphosphate. KLF4 activates the gene encoding the platelet isoform of PFK in breast cancer cells, which enhances their glycolytic activity. By contrast, a metabolic footprint performed with ultraperformance liquid chromatography to quantify the uptake or secretion of amino acids into the media showed that loss of KLF4 stimulated glycolysis without altering respiration in mouse embryonic fibroblasts [78] .
REGULATION OF KLF4 EXPRESSION AND FUNCTION
Cell signaling
The upstream signals that regulate KLF4 expression and activity have been poorly studied, particularly in the hematopoietic system, and range from inflammatory cytokines (IFN-g and TNF-a), Wnt, Notch1, and TCR to respond to oxidative stress or DNA damage (Fig. 2) . Signals emanating from the transmembrane receptor Notch1 induce transactivation of the KLF4 gene during goblet cell differentiation in conjunctival epithelial cells; subsequently, KLF4 promotes the expression of Mucin 5AC, which is required for lubrication of the ocular surface [79] . By contrast, Notch1 inhibits KLF4 expression via HES-1 in the intestinal epithelium, intestinal tumors, and colorectal cancer cells [80] [81] [82] . In ESCs, KLF4 was unable to promote telomerase expression efficiently but was required for the binding of b-catenin to the telomerase promoter, which is downstream of Wnt signaling [23] . This finding highlights the ability of KLF4 to regulate gene expression by assembling transcriptional complexes required for gene regulation, in addition to promoting gene transcription directly via DNA binding. KLF4 inhibits Wnt signaling by interacting with b-catenin and inhibiting the recruitment of p300/CBP to b-catenin and consequently, activating downstream target genes [83] . Cells use various mechanisms to respond to environmental and intracellular stresses, such as inflammation, DNA damage, and oxidative stress. Although levels of inflammatory cytokines increase along with the progression of colon cancer, IFN-g induces the expression of KLF4 via Stat1 signaling in HT-29 cells, despite its tumor suppressor function in the gastrointestinal tract [84] . As KLF4 has been shown to regulate inflammatory responses in macrophages [85] , it is likely that KLF4 expression is optimized to promote an inflammatory milieu in tumors rather than to repress tumor formation, thereby balancing KLF4 functions as an oncogene and tumor suppressor. Perhaps the most studied induction of KLF4 expression is by DNA damage mechanisms that lead to p53-dependent G1/S cell-cycle arrest in colon cancer cells [29] . KLF4 is also regulated by oxidative stress via stimulation with hydrogen peroxide and ferric nitrilotriacetate in vascular smooth muscle cells via the activation of p38 and calcium signaling, as well as the protein synthesis pathway [30] , suggesting a role in the stress response, perhaps by activating stem cells. The expression of KLF4 and heat shock protein 70 is up-regulated by heat stress in different tissues (heart, lung, brain, kidney, and skeletal muscle), probably as a signal to regenerate damaged tissue by promoting the activity of tissuespecific stem cells [86] . 
Transcriptional regulation
Members of the KLF family can contribute to transcriptional networks that activate and repress their own expression in a temporal and spatial manner. The localization of KLFs in intestinal tissues is intimately associated with their functions in cell growth and differentiation. KLF4 is expressed in nonproliferative epithelial cells, which are located in the villi of the small intestine, whereas KLF5 is present in proliferating epithelial cells in the crypt. Thus, the KLF4 gene can be activated by KLF4 and repressed by KLF5 [87] . In ESCs, a "KLF circuitry," composed of KLF2, KLF4, and KLF5, promotes self-renewal by modulating the expression of Nanog, among other pluripotent genes, and this KLF network is preserved by reciprocal control of its own expression in such way that deletion or genomic silencing of a single factor in this triad is sufficient to cripple self-renewal and promote the full differentiation of ESCs [72] . In addition to KLFs, the expression of KLF4 is regulated by other transcription factors, such as CDX2, IRF8, Foxo, ELF4, ZNF750, RARa, and N-Myc (Fig.  2) . The homeobox protein CDX2, which is considered to be a master transcription factor in the intestine, induces the expression of KLF4 upon activation of the gene adenomatous polyposis coli [88] . Therefore, the loss of immunohistochemical detection of CDX2 in surgical specimens has been used as a sensitive marker of intestinal adenocarcinomas. In contrast to epithelial cells, CDX2 overexpression, which is present in .80% of patients with AML, represses KLF4 gene expression by recruiting KDM5B [17] . In normal blood cells, IRF8 activates the KLF4 gene by binding to an upstream enhancer region as a heterodimeric complex with PU.1 during the differentiation of monocytes [89] . Foxo transcription factors inhibit the proliferation of B cells by activating the KLF4 gene; thus, both factors are considered to be promoters of cellular quiescence [90] . Our group reported that the ETS protein ELF4 can directly activate the KLF4 gene in resting, naïve CD8 + T cells and that loss of KLF4, induced using the Mx1-Cre transgene to induce gene deletion, leads to the increased homeostatic expansion of CD8 + T cells [91] . ZNF750 induces KLF4 during late epidermal differentiation and can act to maintain normal skin barrier function via an evolutionarily conserved cysteine 2 histidine 2 (C2H2) zinc finger motif that is downstream of p63 signaling [92] . In vascular smooth muscle cells, the RARa activates KLF4 expression by binding to GC boxes that are located in the proximal promoter [93] . Finally, N-Myc paired with Max, an obligatory Myc partner, regulates expression of KLF2 and KLF4 in neuroblastoma cells [94] . The authors of that study proposed a model in which leukemia inhibitory factor induces the transcription of KLF2, KLF4, and LIN28B via N-Myc:Max dimers. As both N-Myc and KLF4 have been linked to carcinogenesis, it would be interesting to elucidate whether these factors cooperatively promote tumor formation.
Post-transcriptional regulation
Small, noncoding miRs regulate protein expression by reducing mRNA transcript stability and availability for translation (Fig. 2) . The role of miRs in KLF4 expression has been investigated extensively in various cancers, such as esophageal squamous cell carcinoma, glioblastoma, acute lymphoblastic leukemia, bladder cancer, colorectal cancer, pancreatic cancer, and breast cancer [95] [96] [97] [98] [99] [100] . For example, miR-7 reduces KLF4 expression and subsequently decreases p21 levels during epithelial cell transformation in the lung and skin [101] . The expression of miR-145 in differentiating cells, but not in primitive human ESCs, correlates with the inhibitory function of the reprogramming factors KLF4, OCT4, and SOX2 and consequently, of stem cell self-renewal [102] . Conversely, miR profiling performed in mouse embryonic fibroblasts with overexpression of Oct3/4, Sox2, c-Myc, and KLF4 revealed increased expression of the miR-429-200 and miR-17 clusters [103] . Another report showed that miR-137 induces the differentiation of ESCs by targeting KLF4 and T box 3 [104] . In vascular smooth muscle cells, the inhibition of KLF4 downstream of TGF-b and bone morphogenetic protein 4 is mediated by miR-143 and miR-145 [105] . Despite these findings, it is not yet known whether miRmediated regulation of KLF4 is important in hematopoietic cells during their development, differentiation, and function.
Alternative splicing is another post-transcriptional mechanism that regulates the function of transcription factors by generating protein isoforms, preventing the activity of full-length protein, and altering protein subcellular localization. Two major isoforms have been identified for KLF4: KLF4-v1a (deletion of exon 3) and KLF4-v2 (deletion of exons 3 and 4), and their expression is associated with prognosis in patients with pancreatic cancer [106] . Some reports have indicated that coexpression of full-length KLF4 and isoform KLF4v1 has an additive effect in the promotion of cell division, at least in the breast cancer cell line Michigan Cancer Foundation-7 [107] . However, the biologic role of these isoforms in normal and malignant cells is not clearly understood and warrants further investigation.
Post-translational modifications
Transcription factors are often subjected to post-translational modifications (e.g., phosphorylation, ubiquitinylation, sumoylation, and acetylation) that affect protein stability and function (Fig. 2) . ERK1 and ERK2 can inhibit the capacity of KLF4 to regulate transcription during the differentiation of ESCs by direct interaction and the phosphorylation of KLF4. Thus, the inhibition of ERK signaling promotes self-renewal in ESCs by re-establishing KLF4 function [108] . Conversely, p38 MAPK mediates the phosphorylation of KLF4 triggered by TGF-b in vascular smooth muscle cells, although this can cause increased KLF4 activity [109] . In accordance with an inhibitory role on the cell cycle, KLF4 is highly expressed in nonproliferative (quiescent) cells and rapidly down-regulated upon entry into the cell cycle by either loss of transcriptional activators or the ubiquitin-mediated proteolysis of KLF4 [91, 110] . Indeed, TGF-b activates the complex between cadherin 1 and the E3 ubiquitin ligase anaphase-promoting complex, which targets KLF4 for ubiquitination [111] . Four lysine residues in the KLF4 protein were later identified as the major sites of ubiquitination [112] . The role of arginine methylation of KLF4 by PRMT5 was recently described as a mechanism that prevents ubiquitination by the VHL-VHL-elongin B and C ubiquitin protein ligase and promotes tumorigenesis in breast tissues [113] . Consequently, levels of KLF4 and PRMT5 proteins were found to be elevated in breast cancer. Another post-translational mechanism is the addition of a SUMO protein at a single site located in the repressive domain of KLF4. The PIAS1 promotes sumoylation and degradation of KLF4 downstream of TGF-b signaling in smooth muscle cells [114] . Sumoylated KLF4 can activate gene promoters via interactions with SUMO-1 through a SUMO-interacting motif [115] . Moreover, sumoylation inhibits KLF4 transcriptional activity and the capacity to induce pluripotency in somatic cells, while retaining the capacity to induce adipocyte differentiation [116] . As described above, p300 acetylates KLF4 to enhance its transcriptional activity, and in the case of iPSCs, this process is activated by Akt activation.
Epigenetic regulation
Histone modifications and DNA methylation are known to govern the expression of KLF4 in various contexts and throughout different stages of development, differentiation, and carcinogenesis. The study of how KLF4 is regulated at the epigenetic level has been carried out over the past 15 yr, resulting in findings regarding histone acetylation in the KLF4 promoter as a response to the presence of the short-chain fatty acid butyrate [117] . Treatment of colorectal cancer cell lines with butyrate mimics the effects of the HDAC inhibitor trichostatin A by binding to butyrate response elements located in the KLF4 promoter [117] . Subsequent work showed that NO-induced HDAC activity reduced KLF4 expression through a global loss of H3K9 acetylation in mouse ESCs, although neither direct binding of HDACs nor acetylation levels at the KLF4 locus were assessed [118] . H3K9 acetylation of the KLF4 promoter, maintained by the HDAC inhibitor methylselenic acid, was also found to increase KLF4 expression and inhibit the growth of esophageal squamous cell carcinoma cells [119] . HDAC1 expression negatively correlated with that of KLF4 by competing with KLF4 to bind the KLF4 promoter in myeloid leukemia cell lines, whereas genomic silencing increased KLF4 expression and inhibited cell proliferation [120] . More recently, a study of histone acetylation of the KLF4 locus during lung tumorigenesis revealed that the inhibition of elevated levels of HDACs, particularly HDAC3, resulted in enhanced KLF4 expression [121] . Overall, a complete picture of the "writers" and "erasers" of histone acetylation has yet to be realized; it is clear that KLF4 expression changes the antitumor effects exerted through HDAC inhibitors.
In addition to acetylation, the balanced distribution of activating and repressing histone methylation marks contributes to the regulation of KLF4. For example, KLF4 repression can result from a bivalent locus with activating (H3K4me3) and repressing (H3K27me3) histone marks, but loss of the H3K27me3 mark allows for H3K4me3-mediated activation of the KLF4 locus [122] . In prostate cancer cells, HDAC inhibitors were unexpectedly found to increase H3K4me3 by Sp1-dependent cross-talk between HDACs and histone demethylases, resulting in repressive epigenetic remodeling [123] . Loss of polycomb-like 2, a protein associated with the polycomb repressive complex 2, regulates ESC self-renewal by reducing the H3K27me3 mark at the KLF4 promoter region and increasing KLF4 expression [124] . Interestingly, inhibition of the only known H3K79 methyltransferase, DOT1L, restored colony formation of iPSCs with Oct4/c-Myc/ Sox1 in the absence of KLF4 [125] . Recent reports have identified site-and context-specific coordinated changes in H3K4me3 and H3K27me3 that can modulate KLF4 expression levels, although the responsible writers have not been identified in all cases. KDM5B plays a role in the removal of H3K4me3 marks in AML cell lines, and a study of switch/sucrose nonfermentable-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1 in ESCs revealed its regulation of KLF4 and other bivalent genes through administration of H3K27me3 repressive marks. Overall, these studies, most of which have examined cancer and stem cell models, outline a framework in which KLF4 is regulated by the coordinated addition and removal of activating and repressive histone methylation marks that are deposited by chromatin-remodeling proteins in a cell contextdependent manner. The identification of the epigenetic proteins that act at these specific stages of differentiation and development and the determination of why and how they are regulated are important questions that should be addressed.
Most epigenetic studies of the KLF4 gene locus have focused on DNA methylation of CpG island regions that span its promoter and the coding region (exons 1 and 2), which predominantly occurs in cancer cells. KLF4 expression was found to be significantly diminished in adult T cell leukemia as result of hypermethylation of CpG sites in the promoter, although the extent of methylation was greater in the ATL-43T cell line than in primary patients with acute T cell leukemia [126] . Accordingly, treatment of ATL-43T cells with 5-Aza, but not HDAC inhibition, restored KLF4 expression [126] . Similar studies in colorectal cancer [13] , gastric cancer [127, 128] , classic and non-Hodgkin lymphoma [14] , medulloblastoma [129] , renal cell carcinoma [130, 131] , hepatocellular carcinoma [132] , urothelial cancer [133] , cervical cancer [134] , and splenic marginal zone lymphoma [135] have identified KLF4 repression acting through DNA methylation as a common marker for malignancy and prognosis. A hemodynamic study revealed that the de novo DNMT3a exhibited increased expression and binding to the KLF4 locus in human aortic endothelial cells when exposed to a disturbed fluid-flow environment. Thus, methylation of the KLF4 promoter was reduced by treatment with the DNMT3a inhibitor RG108 [136] . This finding suggests that DNMT3a may be responsible for the mechanosensitive methylation of the KLF4 promoter. Likewise, DNMT1 plays a role in the methylation of the KLF4 promoter in the context of umbilical cord endothelial cells and renal fibrosis following unilateral ureteral obstruction or TGF-b administration [137, 138] . Recently, a connection between RNA splicing and DNA methylation was described for hepatocellular carcinoma, in which the expression of a noncoding KLF4 transcript containing a 102 nucleotide intron insertion in cancerous samples is reduced by methylation of a CpG island proximal to the intron and restored by treatment with 5-Aza [139] . Despite these advances in the role of the epigenome in KLF4 expression in cancer, data obtained using normal blood cells unfortunately remain limited. During the differentiation of macrophages, reduction in methylation of the KLF4 promoter mediated by activation-induced cytidine deaminase allows for the transcription factor PU.1 to bind and induce gene expression in monocytes [140] . Overall, the KLF4 gene is regulated at the epigenetic level by various context-dependent mechanisms that have yet to be completely elucidated.
ROLE OF KLF4 IN HEMATOPOIESIS
Maintenance of primitive hematopoietic progenitor cells
A landmark publication reported that KLF4 cooperates with Sox2, Oct4, and c-Myc to induce pluripotency in human and murine somatic cells [141] . The contribution of KLF4 during reprogramming of somatic cells into PSCs suggested a potential function in stemness of primitive progenitor cells and maintenance of an undifferentiated state. Indeed, a "KLF triad" composed of KLF2, KLF4, and KLF5 has been shown to promote self-renewal in ESCs derived from early preimplantation embryos [72, 142] . Accordingly, the silencing of the expression of a single factor in this triad is sufficient to promote ESC differentiation by crippling the capacity of these cells to undergo self-renewing divisions. These findings suggest that KLF4 maintains stemness in tissue-specific stem cells by setting a pattern of gene expression that promotes self-renewal during cell divisions. The high level of KLF4 expression found in human HSCs (CD34 + CD38 lo Lineage lo ) led to a study of the role of KLF4 in primitive hematopoietic progenitor cells using HSCs from 14.5 d postcoitum fetal livers of Klf4-null embryos, as embryonic homozygous deletion alters skin permeability and causes postnatal lethality [143, 144] . The clonogenicity of myeloid progenitors present in the fetal liver, as measured in methylcellulose cultures, showed no significant differences between wild-type and Klf4 2/2 cells nor in their capacity to reconstitute cytoablated hosts in competitive repopulating assays [143] . Although these findings excluded a role for KLF4 in fetal HSCs, they do not preclude functional defects in bone marrow HSCs, which have yet to be investigated. In support of a regulatory role for KLF4 in HSCs, loss of the cell fate determinant lethal(2) giant larvae protein homolog 1 resulted in increased numbers and repopulating capacities of HSCs in competitive and serial bone marrow transplantations as a consequence of increased self-renewing cell divisions that were associated with the repression of KLF4 and early growth response protein 1 [145] . In addition to the cell-intrinsic regulation, HSC niches supported by mesenchymal and endothelial cells in bone marrow play critical roles in stem cell maintenance [146] . Although KLF4 regulates vascular endothelial cells [147] , there are not reports indicating a functional role in sinusoidal blood vessels, specialized venules that form a reticular network of fenestrated vessels in the vascular niche. Thus, more studies should be carried out in adult HSCs or the microenvironment with lineage-specific or inducible deletion of the Klf4 gene to evaluate whether KLF4 directly or indirectly preserves stemness (quiescence, self-renewal, and multipotency) of adult bone marrow stem cells.
Myeloid cell development
Monocytes. Monocytes are circulating blood cells of a myeloid origin with phagocytic properties that render them able to differentiate further into macrophages upon extravasation into different tissues. Monocytes develop in the bone marrow by the differentiation of CMP cells via GMPs. Although previous studies have focused on epithelial cells, identification of KLF4 in a screen of a macrophage/monocyte cDNA library increased interest in its role in hematopoietic cells [85] . The inflammatory cytokine IFN-g promotes KLF4 expression via Stat1 in the cell lines THP-1 and J774 and in human blood monocyte-derived macrophages [85] . In addition to IFN-g, TNF-a and LPS could induce KLF4 expression in monocytic cells, whereas TGF-b appeared to inhibit KLF4 expression. Ectopic overexpression of KLF4 induced monocytic differentiation and transactivation of the CD14 promoter downstream of PU.1 in human promyelocytic leukemia 60 cells and most importantly, skewed differentiation of primary HSCs and CMPs toward the monocytic lineage; therefore, restoration of KLF4 could correct the deficit of monocytes observed in PU.1-null fetal liver cells [148] . Furthermore, ex vivo deletion of the Klf4-floxed gene in CMPs by transduction with a retrovirus that encoded Cre-recombinase diminished the ability of these cells to differentiate into mature monocytes [148] . These findings were corroborated independently by another group, who used fetal liver cells from Klf4-null embryos, and by our group, who used somatic deletion of a Klf4-floxed gene in Vav-Cre and Mxi1-Cre transgenic mice [10, 143] .
PU.1 regulates the early commitment of HSCs to CMPs, whereas IRF8 and KLF4 promote differentiation at later stages [149] . Irf8 2/2 mice exhibit lower numbers of CD11b + CD115 + Ly6C + cells in the blood, spleen, and bone marrow [89] . Genome-wide analysis revealed that IRF8 and PU.1 regulate KLF4 gene expression by binding to enhancer regions distal to the transcription start sites and promoting the formation of enhancers based on the genomic distribution of H3K4 monomethyl [89] . That study also found that temporal gene expression, regulated sequentially by PU.1, IRF-8, and KLF4, plays a critical role in monocyte development. Thus, inflammation induces the migration of monocytes from the bloodstream to sites of infection where abundant IFN-g sequentially activates IRF8 and KLF4 to promote macrophage differentiation.
Macrophages. Monocytes can differentiate into phagocytic cells, better known as macrophages, which are specialized in engulfing damaged or dead cells, presenting antigens to immune cells to trigger adaptive immune responses, and secreting pro-and antiinflammatory cytokines. Environmental signals can modulate the differentiation of macrophages into M1 or M2 subtypes, which are distinguished by their capacity to promote (TNF-a, IL-6, reactive oxygen species) or prevent (IL-10) inflammation, respectively. KLF4 mediates inflammation by activating expression of the iNOS gene via DNA binding, while inhibiting plasminogen activator inhibitor type 1 downstream of TGF-b1 signaling by competing with mothers against decapentaplegic homolog 3 for p300/CBP [85] . It was subsequently shown that KLF4 cooperates with Stat6 to induce M2 differentiation and regulate IL-10 expression [150, 151] . More recently, it was shown that KLF4 promotes M2 polarization downstream of IL-4 signaling by activating the monocyte chemoattractant protein-induced protein gene, which encodes for the MCP-1-induced protein that has RNAse and antiDicer activity and is known to inhibit M1 polarization [152] . Additionally, ethanol induces KLF4 expression and promotes the differentiation of M2 macrophages in alcoholic liver disease [153] . KLF4 represses the expression of the ETS transcription factor Etslike protein 3 in Raw 264.7 cells treated with LPS, which has been associated with a reduction of bacterial phagocytosis. However, it remains unclear how LPS activates the expression or function of KLF4 [154] . Finally, an exciting new report shows that KLF4 mediates the transition of smooth muscle cells into macrophagelike cells during atherosclerotic plaque formation [155] , suggesting that KLF4 may play important roles in cellular de-differentiation and differentiation, as well as in the trans-differentiation of somatic cells.
DCs. The adaptive immune system is "blind" to unprocessed pathogens, unless DCs, also known as antigen-processing cells, digest pathogens into small antigenic epitopes that can be presented to T and B cells to prime an antigen-specific response. DCs develop in the bone marrow and can have a lymphoid and myeloid origin. Our group has reported that KLF4 promotes the survival of NK cells in the spleen by maintaining a pool of cDCs in this tissue [10] . More recently, the group of Murphy reported that KLF4 is required in IRF4-expressing cDCs to promote Th2 but not Th17 cell responses [156] . With the use of conditional deletion of the Klf4 gene in hematopoietic cells (Vav-Cre) or DCs (Itgax-Cre), this group was able to show that a lower response to Schistosoma mansoni infection was caused by impaired development of pre-cDC progenitors in the bone marrow and diminished antigen transport from the skin to lymph nodes [156] . More studies will be needed to identify KLF4 target genes and to determine the molecular pathways involved in the regulation of cDCs and their impact on immunity.
Although tumorigenesis is not a main focus of this article, MDSCs are a population of early progenitors of monocytes, macrophages, and DCs that can infiltrate in tumors and inhibit the function of lymphocytes. These MDSCs can have markers similar to those used to identify monocytes (i.e., CD11b, Gr1) and differentiate into fibrocytes during tumor metastasis, a process that is regulated by KLF4 [157] . KLF4 also promotes the development of MDSC in the bone marrow by inducing GM-CSF production via regulation of CXCL5 [158] . Therefore, the targeting of KLF4 to prevent metastasis represents an emerging field in oncology.
Development and function of lymphoid cells
T cell development in thymus. HSC-derived pro-T migrate from the bone marrow to the thymus to complete development into monospecific and non-self-reactive CD4 + and CD8 + T cells (Fig. 3) . The role of the family of KLFs in lymphocyte biology has been reviewed elsewhere [2, 159] . The enrichment of KLF4 transcripts in CD4 and CD8 DN thymocytes, compared with DP and SP CD8 + T cells, suggested a potential role in early stages of thymic development [9] . Transgenic expression of KLF4, driven under the CD2 promoter, impaired the transition from DN2 (
+ ) thymocytes, an early stage of thymocyte development in which immature thymocytes commit to the T cell lineage [160] . However, our group later showed that deletion of the floxed Klf4 gene by Cre-recombinase, driven by the Vav promoter, resulted in a normal distribution of thymocyte subsets (DN subsets, DP, and CD4 and CD8 SP cells). A lower thymic cellularity in KLF4-deficient mice was not caused by alterations in cell proliferation and survival or by the reduced migration of bone marrow-derived pro-T to the thymus, as the numbers of common lymphoid progenitor cells in the bone marrow and early thymic precursors in the thymus were not grossly affected by the loss of KLF4 [9] . These studies indicate that KLF4 downregulation is required, and KLF4 has a redundant role during the DN2-DN3 transition.
CD8 T cells. T cells can proliferate in response to homeostatic signals and antigen-driven stimuli. Pathogen infection can trigger a series of events: activation of pathogen-specific naïve T cells, expansion of effector T cells, cell death and contraction of effector T cells, and emergence of immunologic memory aimed at rapid responses to secondary encounters with the same pathogen. We found that the transcription factor ELF4, a member of the ETS family of proteins, restricts the proliferation of naïve CD8 + T cells by directly activating the Klf4 gene downstream of TCR signaling [91] . Therefore, TCR activation led to a rapid reduction in the expression of ELF4, followed later by KLF4 down-regulation and ultimately, reduced expression of the cdk inhibitor p21 and cell-cycle arrest. Interestingly, inhibition of mammalian target of rapamycin with rapamycin prevented down-regulation of KLF4 in naïve CD8 T cells but not in CD4 T cells [161] . As a proof of principle for a linear pathway, deletion of the Klf4-floxed gene using a Mx1-Cre transgene resulted in increased cell division of naïve CD8 + T cells triggered by in vitro TCR cross-linking, although not to the extent of Elf4-null T cells, as ELF4 additionally maintains the pool of dual-specificity phosphatases that can restrict TCRdriven ERK activation [91] . Further studies using Vav-Cre to delete the Klf4 gene indicated that KLF4 inhibits TCR-mediated but not homeostatic proliferation of CD8 + T cells [9] .
Consequently, activation of KLF4-deficient CD8 + T cells generated increased numbers of functional memory CD8 + T cells in both primary and recall responses. CD4 T cells. The role of KLF4 in the development, differentiation, and function of CD4 + T cells has been less thoroughly explored than in CD8 + T cells. Naïve CD4 T cells have a plasticity that enables their differentiation into multiple lineages of Th cells (i.e., Th1, Th2, Th17, Tf, and T reg ) in a manner that is dependent on a combination of cell-intrinsic factors and the inflammatory milieu. A report showed that KLF4 is required for the differentiation of Th17 cells by regulating IL-17a gene expression, whereas differentiation toward the Th1 and T reg lineages remained unaffected [162] . That study used CD4 + T cells, purified from chimeric mice, generated by transplantation of fetal liver cells from mice that carried a homozygous embryonic deletion of the Klf4 gene. Consistent with this finding, another group showed that CD4-Cre-mediated deletion of the Klf4 gene in T cells resulted in lower proliferative capacity and a modest reduction in the number of thymocytes [163] . Additionally, Klf4-null CD4 + T cells, cultured under Th17-polarizing conditions, generated lower numbers of Th17-type T cells compared with controls, although this finding could have been a consequence of the lower expression of the IL-17a gene, which was used to enumerate Th17 cells, rather than a developmental impairment [163] . In both studies, the in vivo Th17 polarization of Klf4-null CD4 + T cells significantly ameliorated disease progression in a model of induced experimental autoimmune encephalomyelitis [162, 163] . More recently, the increased frequency of Th17 cells observed in patients with dermatomyositis, an inflammatory disease marked by muscle weakness and skin rashes, was associated with lower levels of miR-206 and concomitantly increased KLF4 levels and the differentiation of Th17 cells [164] . That study highlights that individuals with an underlying KLF4 deficiency caused by epigenetic, transcriptional, or post-transcriptional mechanisms could alter Th17-mediated responses to inflammation.
B cells. B cells develop in the bone marrow, further mature in the spleen, and are responsible for the humoral adaptive immune response. Antigen response generates an initial expansion of antigen-specific naïve B cells, leaving behind a small number of memory B cells, which can rapidly respond to secondary encounters of the same antigen. Similar to T cells, KLF4 is rapidly down-regulated upon activation of the BCR and remains down-regulated in memory B cells to facilitate rapid responses to secondary infections through the suppression of this cell-cycle inhibitor [44, 165] . Overexpression of KLF4 in B cells induces cell-cycle arrest downstream of FOXO, although loss of function does not result in alterations in the cell cycle, suggesting that another KLF likely compensates for the loss of KLF4 [90] . Finally, iPSCs derived from B cells were strikingly able to differentiate into T cells, but not B cells following expression of KLF4 and the other 3 reprogramming factors, although it is not clear whether this was caused by a technical inability to differentiate iPSCs into B cells [166, 167] .
NK cells. As part of the innate immune system, NK cells induce the cytolysis of cells infected with viruses or that are undergoing malignant transformation. Deletion of the Klf4 gene using 2 Crerecombinase transgenic systems (Mx1-Cre + polyinosinic:polycytidylic acid and Vav-Cre) resulted in decreased numbers of NK cells (NK1.1 + TCRb 2 ) in the spleen, whereas the distribution of these cells in the liver, bone marrow, and spleen was comparable with that of controls [10] . NK cells develop in the bone marrow and undergo further differentiation in the peripheral organs, which "fine tune" NK cell function for specific tissues. The immunophenotypic identification of NK cell subsets based on the expression of CD27 and CD11b showed a significant reduction of intermediate and mature NK cells in the spleen of mice with a somatic deletion of the Klf4 gene [10] . KLF4 regulates survival, rather than the development and differentiation, of NK cells in peripheral tissues, especially the spleen, as the numbers of progenitors and immature and mature NK cells were normal in the bone marrow despite increased numbers of apoptotic NK cells in the spleen. A combination of reciprocal bone marrow chimeras to study the role of radio-sensitive (hematopoietic) and radioresistant (nonhematopoietic) tissues revealed that the microenvironmental factors that supported the survival of splenic NK cells were of a hematopoietic origin. Indeed, KLF4 maintained the pool of bone marrow-derived and short-lived DCs in the spleen to support NK cell survival via IL-15 trans-presentation.
CONCLUDING REMARKS
In addition to numerous roles for KLF4 in normal and cancerous epithelial cells, KLF4 has emerged as an important regulator of hematopoietic myeloid cells and lymphocytes. Further studies of the underlying mechanism in these processes are warranted to improve our understanding of blood formation at the steady state, during hematologic regeneration postinjury, such as for chemotherapy and bone marrow transplant recipients, and during the leukemogenic process. 
DISCLOSURES
The authors declare no conflicts of interest.
